Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition

SIMPLE SUMMARY: Although the initial clinical response of ovarian cancer patients to first-line platinum-based chemotherapy is often excellent, most patients relapse and develop resistance to treatment. However, the mechanism underlying resistance is unclear. DNA repair is the best-known effector of...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Manman, Huang, Xi, Zheng, Cuimiao, Long, Junming, Dai, Qingyuan, Chen, Yangyang, Lu, Jingyi, Pan, Chaoyun, Yao, Shuzhong, Li, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776316/
https://www.ncbi.nlm.nih.gov/pubmed/36551554
http://dx.doi.org/10.3390/cancers14246068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776316/
https://www.ncbi.nlm.nih.gov/pubmed/36551554
http://dx.doi.org/10.3390/cancers14246068

Ejemplares similares